Cathay Biotech Inc.
688065.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.39 | -2.59 | -1.92 | 1.10 |
| FCF Yield | -0.10% | -3.13% | -9.51% | -1.61% |
| EV / EBITDA | 28.09 | 62.87 | 45.45 | 68.61 |
| Quality | ||||
| ROIC | 2.75% | 2.44% | 3.78% | 4.02% |
| Gross Margin | 28.28% | 27.40% | 33.97% | 35.42% |
| Cash Conversion Ratio | 1.73 | 1.55 | 1.31 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.61% | -3.65% | 17.70% | 7.24% |
| Free Cash Flow Growth | 97.76% | 70.53% | -285.54% | -254.82% |
| Safety | ||||
| Net Debt / EBITDA | -5.13 | -8.01 | -7.69 | -13.31 |
| Interest Coverage | 16.48 | 12.00 | 28.76 | 44.40 |
| Efficiency | ||||
| Inventory Turnover | 1.80 | 1.05 | 1.02 | 1.29 |
| Cash Conversion Cycle | 13.30 | 22.43 | 187.37 | 253.64 |